Peters Township, PA 15317
Shopping Cart
Your Cart is Empty
Quantity:
Subtotal
Taxes
Shipping
Total
There was an error with PayPalClick here to try again

Kingridge Kennels English Labrador Retrievers
Intelligent ~ Calm ~ Beautiful
Neurologically Stimulated, Lovingly Socialized & Trained
Lab Tails of Kingridge
Blog
The Kingridge 2016 Winter Litter Has Arrived
Posted on December 2, 2016 at 1:31 PM |
What an intense 24 hours! Annie labored beautifully from 11:00 last night until 7:00 this morning. After a long sleepless night, she eventually ran out of steam. We went to the vet's for a little help, because of the slow progress. We knew that there was the potential for a C-Section to help save as many pups as possible. Ultimately, we did not need to have surgery, but 2 puppies were lost. It was so sad, but we are elated with the 6 beautiful newborn Labradors that we welcomed into this world during these past 14 hours. It was a very intense and prolonged labor, and I know Annie and I are definitely ready for some much needed rest. I will be posting more details about the puppies in this litter after I take a long sweet rewarding nap... Just like mama Annie. She deserves it! She did an absolutely stellar job, and is the sweetest mom I have ever seen. Praise God for beautiful healthy pups! |
Categories: Expecting Puppies, Our Puppies
Post a Comment
Oops!
The words you entered did not match the given text. Please try again.
29 Comments
Loading...

Reply
tcsgroupo
2:55 PM on February 28, 2022
cidofovir, brand name vistide, is an injectable antiviral medication primarily used as a treatment for cytomegalovirus (cmv) retinitis (an infection of the retina of the eye) in people with aids.
cidofovir was approved for medical use in 1996.
medical use
dna virus
its only indication that has received regulatory approval worldwide is cytomegalovirus retinitis. cidofovir has also shown efficacy in the treatment of aciclovir-resistant hsv infections. cidofovir has also been investigated as a treatment for progressive multifocal leukoencephalopathy with successful case reports of its use. despite this, the drug failed to demonstrate any efficacy in controlled studies. cidofovir might have anti-smallpox efficacy and might be used on a limited basis in the event of a bioterror incident involving smallpox cases. brincidofovir, a cidofovir derivative with much higher activity against smallpox that can be taken orally has been developed. it has inhibitory effects on varicella-zoster virus replication in vitro although no clinical trials have been done to date, likely due to the abundance of safer alternatives such as aciclovir. cidofovir shows anti-bk virus activity in a subgroup of transplant recipients. cidofovir is being investigated as a complementary intralesional therapy against papillomatosis caused by hpv.
it first received fda approval on 26 june 1996, tga approval on 30 april 1998 and ema approval on 23 april 1997.
it has been used topically to treat warts.
cidofovir was approved for medical use in 1996.
medical use
dna virus
its only indication that has received regulatory approval worldwide is cytomegalovirus retinitis. cidofovir has also shown efficacy in the treatment of aciclovir-resistant hsv infections. cidofovir has also been investigated as a treatment for progressive multifocal leukoencephalopathy with successful case reports of its use. despite this, the drug failed to demonstrate any efficacy in controlled studies. cidofovir might have anti-smallpox efficacy and might be used on a limited basis in the event of a bioterror incident involving smallpox cases. brincidofovir, a cidofovir derivative with much higher activity against smallpox that can be taken orally has been developed. it has inhibitory effects on varicella-zoster virus replication in vitro although no clinical trials have been done to date, likely due to the abundance of safer alternatives such as aciclovir. cidofovir shows anti-bk virus activity in a subgroup of transplant recipients. cidofovir is being investigated as a complementary intralesional therapy against papillomatosis caused by hpv.
it first received fda approval on 26 june 1996, tga approval on 30 april 1998 and ema approval on 23 april 1997.
it has been used topically to treat warts.
/
Oops!
Oops, you forgot something.